We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PRAC Takes a Closer Look at Anti-Cancer/Skin Drug
The EMA’s Pharmacovigilance Risk Assessment Committee is considering recommending more rigorous patient screening before starting treatment with a common family of anti-cancer and topical skin cream drugs.